Title Collaboration Type HHS Participating Agencies NIH Participating Institutes, Centers, and Offices Description
Action for Health in Diabetes (Look AHEAD) Research Initiative CDC, IHS NIDDK, NHLBI This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. Enrollment occurred between 2001-2004 with a planned follow-up of up to 13.5 years. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. The study intervention was discontinued in Sept. 2012 on the recommendation of the Data and Safety Monitoring Board (DSMB), as there were no differences between the two groups after up to 11 years of follow-up. The study will continue to follow participants for study outcomes.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-up Study (ACCORDION) -- Health Related Research Initiative CDC NHLBI The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was primarily composed of three clinical trials that tested treatment approaches to determine the best ways to decrease the high rate of major cardiovascular disease (CVD) events – heart attack, stroke, or death from CVD – among people with type 2 diabetes who are at especially high risk of having a CVD event, like a heart attack or stroke. ACCORDION (the ACCORD Follow-up Study) is a prospective, observational follow-up study of approximately 8000 participants who were treated and followed in the ACCORD Trial. It is designed to further elucidate and clarify the long-term effects of the ACCORD treatment strategy and provide additional data on the long-term relationships among various cardiovascular and diabetic risk factors. ACCORD participants had type 2 diabetes and were at high risk for a CVD event. Those who agree to participate in ACCORDION will continue to be followed through clinic and phone visits for an average of 3.5 years in the period 2011 through 2014. Participants will be seen in 76 clinics across the United States and Canada. The CDC is contributing intellectually and financially to the Health Related Quality of Life and Cost Effectiveness substudies of the trial. "
Addiction Technology Transfer Center Resource Development SAMHSA NIDA Accelerating the dissemination of research-based drug abuse treatment into clinical practice is a priority for the National Institute on Drug Abuse (NIDA) and represents the core mission of the Blending Initiative. NIDA and the Substance Abuse and Mental Health Services Administration (SAMHSA) joined together to create the Blending Initiative in 2001 to reduce the gap that exists between the publication of research results and impact on treatment delivery. This initiative incorporates collaboration between clinicians, scientists, and experienced trainers to catalyze the creation of user-friendly treatment tools and products and facilitate the adoption of research-based interventions into front-line clinical settings. Through this initiative, NIDA and SAMHSA’s Addiction Technology Transfer Centers (ATTCs) disseminate treatment and training products based on results from studies conducted by the National Drug Abuse Clinical Trials Network (CTN) as well as other NIDA-supported research.
Adjuvant Working Group Committee, Work group, Advisory group, or Task Force FDA NIAID, NCI Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from The Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources.
Administration for Community Living (ACL) - NIA Partnership Other ACL NINR, NIA, NIDCR, NIMH, NIMHD, NINDS This group is made up of representatives from the Administration for Community Living, National Institute on Disability and Rehabilitation Research, National Institute on Aging, National Insitute of Nursing Research, and National Center for Medical Rehabilitation Research (NICHD) who are working to identify evidence-based interventions that are ready for dissemination and implementation in community programs and collaboratively support their translation into the community. The group will: work collaboratively to promote dissemination, implementation, and evaluation of promising scientific findings; translate evidence-based interventions to inform policy and improve practice; strengthen the capacity of each respective agency to enhance the health, well-being, and independence of older adults and people with disabilities across the life span, and in various environments. Areas of interest include topics such as: health and wellness; new models of care; community living and participation; and caregiving.
Administration of Comprehensive Assessment of Occupationally-Relevant Exposures Research Initiative CDC NIEHS This task order provides financial support for The National Institute for Occupational Safety and Health (NIOSH) personnel to travel to, attend, and participate in several National Toxicology Program (NTP) meetings held in Research Triangle Park, NC, and Washington, DC. These included Interagency Committee for Chemical Evaluation and Coordination meetings, NTP Technical Report meetings, NTP Board of Scientific Counselors meetings, Report on Carcinogens meetings, NTP Executive Committee Meetings, and ad hoc meetings addressing specific NTP issues. All of these meetings were aimed at investigating, defining, or reporting hazards associated with exposure to environmental chemicals. Many of the exposures are occupational and NIOSH personnel provide expert opinion on chemical exposures linked to cancer, respiratory disease, development and reproductive disorders, neurotoxicity, and immunological toxicity.
Adolescent Health Working Group Committee, Work group, Advisory group, or Task Force ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA NIMH, NICHD, NIDA This interagency workgroup focuses on three current near-term priorities: (1) enrolling eligible adolescents in Medicaid and Children''s Health Insurance Program; (2) preventing and addressing mental disorders and promoting mental wellness in adolescents; and (3) youth engagement. NIMH staff worked with SAMHSA to draft a framework of strategies to adddress mental disorder and promote mental wellness in adolescents. This framework identified opportunities that could be implemented with existing resources, and proposed ideas would need additional resources.
Adults with Chronic Health Care Needs (ACHCN) Screener Cognitive Testing Research Initiative CDC CC A screening instrument developed to provide the health services research community with the capacity to estimate the size of and measure the subsequent health care needs and use among individuals with chronic conditions and/or disabilities at the population level is undergoing in-depth cognitive testing by the Questionnaire Design Research Laboratory in NCHS.
Advanced Anticonvulsant System Interagency Product Team Committee, Work group, Advisory group, or Task Force FDA, OS NINDS The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure.
Advancing Regulatory Science through Novel Research and Science-Based Technologies Research Initiative FDA OD/DPCPSI, NCATS, NIDDK, NINDS, OD/DPCPSI/OSC This regulatory science initiative aims to foster the development, evaluation and availability of new or improved tools, methods, standards, and applied science that support a better understanding and improved evaluation of product safety, quality, effectiveness, and manufacturing throughout the product life cycle.